141
Participants
Start Date
June 11, 2021
Primary Completion Date
December 3, 2024
Study Completion Date
October 31, 2026
Valemetostat tosylate
200mg QD continuously until disease progression, consent withdrawal, unacceptable drug-related toxicity, lost to follow-up, major protocol deviation, pregnancy, termination by sponsor or death, whichever occurs first.
CH Tourelle Peltzer, Verviers
A.Z. Sint Jan AV, Bruges
University Hospital Gent, Ghent
Institut Paoli Calmette, Marseille
Institut d'Hématologie de Basse Normandie, Caen
CHU de Dijon, Dijon
Institut Bergonié, Bordeaux
CHU de Montpellier, Montpellier
CHU Pontchaillou, Rennes
CHU Hôtel Dieu, Nantes
Ch de Bretagne Atlantique -, Vannes
Service des Maladies du Sang - CHRU de Lille, Lille
CHU d'Estaing, Clermont-Ferrand
CH de la Côte Basque, Bayonne
Gh Region Mulhouse Et Sud Alsace, Mulhouse
Emmanuel Bachy, Pierre-Bénite
Clinique Victor Hugo, Le Mans
Ch Metropole Savoie - Site Chambery, Chambéry
CH d'Avignon, Avignon
Chd de Vendee, La Roche-sur-Yon
François Lemonnier, Créteil
CHU Mont-Godinne, Yvoir
Collaborators (1)
Daiichi Sankyo
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER